NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01243944,Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial),https://clinicaltrials.gov/study/NCT01243944,,COMPLETED,This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).,YES,Polycythemia Vera,DRUG: ruxolitinib tablets|OTHER: Best Available Therapy (BAT),"The Percentage of Participants Achieving a Primary Response at Week 32, Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32)., 32 Weeks","The Percentage of Participants Achieving a Durable Primary Response at Week 48, Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization., 48 Weeks|The Percentage of Participants Achieving Complete Hematological Remission at Week 32, Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10\^9/L and a white blood cell count less than or equal to 10 X 10\^9/L., 32 Weeks|The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48, Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization., 48 Weeks|The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48, Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization., 48 Weeks|The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48, Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization., 48 Weeks|Estimated Duration of the Primary Response, Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response).

Kaplan-Meier estimates are provided for duration of primary response., Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study|The Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32, Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria., 32 Weeks|The Percentage of Participants Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48, Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization., 48 Weeks|Estimated Duration of the Complete Hematological Remission, Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response).

Kaplan-Meier estimates are provided for duration of complete hematological remission., Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study|Duration of the Absence of Phlebotomy Eligibility, Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression., 256 Weeks|Duration of Reduction in Spleen Volume, Duration of spleen volume reduction is defined as the time from the first occurrence of a \>=35% reduction from baseline in spleen volume until the date of the first documented progression., 256 Weeks|Duration of The Overall Clinicohematologic Response, Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression., 256 Weeks",,Incyte Corporation,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,222,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CINC424B2301,2010-10-27,2014-01-15,2018-02-09,2010-11-19,2015-03-06,2019-03-06,"Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Pomona, California, United States|Sacramento, California, United States|San Diego, California, United States|Bridgeport, Connecticut, United States|New Haven, Connecticut, United States|Boynton Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Winter Park, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Lafayette, Louisiana, United States|Scarborough, Maine, United States|Baltimore, Maryland, United States|Columbia, Maryland, United States|Southfield, Michigan, United States|Jefferson City, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Seattle, Washington, United States|Buenos Aires, Argentina|Brisbane, Australia|Parkville, Australia|Tweed Heads, Australia|Antwerp, Belgium|Brugge, Belgium|Bruxelles, Belgium|Leuven, Belgium|Hamilton, Canada|Montreal, Canada|Toronto, Canada|Beijing, China|Hangzhou, China|Avignon, France|Bayonne, France|Brest, France|Lille, France|Nantes, France|Paris, France|Vandœuvre-lès-Nancy, France|Aachen, Germany|Berlin, Germany|Bonn, Germany|Freiburg, Germany|Hamburg, Germany|Jena, Germany|Magdeburg, Germany|Mannheim, Germany|Minden, Germany|Munchen, Germany|Ulm, Germany|Budapest, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szombathely, Hungary|Bari, Italy|Bergamo, Italy|Bologna, Italy|Firenze, Italy|Milano, Italy|Napoli, Italy|Orbassano, Italy|Pavia, Italy|Reggio Calabria, Italy|Roma, Italy|Varese, Italy|Vicenza, Italy|Chiba, Japan|Chuo-city Yamanashi, Japan|Maebashi, Japan|Nagoya-city Aichi, Japan|Osaka, Japan|Tokyo, Japan|Seoul, Korea, Republic of|Enschede, Netherlands|Rotterdam, Netherlands|Moscow, Russian Federation|St. Petersburg, Russian Federation|Barcelona, Spain|Coruña, Spain|Las Palmas de Gran Canaria, Spain|Madrid, Spain|Majadahonda, Spain|Malaga, Spain|Pamplona, Spain|Salamanca, Spain|Valencia, Spain|Bangkok, Thailand|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Bournemouth, United Kingdom|Cardiff, United Kingdom|London, United Kingdom",
